Commerzbank Aktiengesellschaft’s Celldex Therapeutics CLDX Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,975	Closed	-$465K	–	1053
2015 Q4	$465K	Buy	1,975 +88	+5%	+$19.2K	﹤0.01%	894
2015 Q3	$298K	Sell	1,887 -4,240	-69%	-$1.2M	﹤0.01%	955
2015 Q2	$2.32M	Sell	6,127 -706	-10%	-$280K	0.01%	562
2015 Q1	$2.86M	Sell	6,833 -34,954	-84%	-$12.5M	0.02%	510
2014 Q4	$11.4M	Buy	41,787 +374	+0.9%	+$93K	0.07%	238
2014 Q3	$8.05M	Buy	41,413 +23,644	+133%	+$5.15M	0.03%	366
2014 Q2	$4.35M	Buy	+17,769	New	+$4.01M	0.02%	496

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Commerzbank Aktiengesellschaft's CLDX Position: Q1 2016 in Review

Commerzbank Aktiengesellschaft sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 1,975 shares — an estimated $465K sold.

Commerzbank Aktiengesellschaft first reported a position in CLDX in Q2 2014 and held it in 7 quarters. The position peaked at $11.4M in Q4 2014. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

Commerzbank Aktiengesellschaft reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
Commerzbank Aktiengesellschaft sold 1,975 Celldex Therapeutics shares in Q1 2016, an estimated $465K.
Commerzbank Aktiengesellschaft first reported a position in Celldex Therapeutics in Q2 2014 and held it in 7 quarters.
Commerzbank Aktiengesellschaft's Celldex Therapeutics position peaked at $11.4M in Q4 2014.
145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q1 2016, filed 10 May 2016.